logo
ScreenersREIT EarningsREIT SectorsMarketplaceLearn
Logo

Cellectis S.A.

CLLS

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, suchā€¦ read more

Healthcare

Biotechnology

8 years

USD

Exclusive to Premium users

Price

per share adjusted in USD

$2.85

Price

-0.35%

-$0.01

$2.86

Previous Close

$2.94

Open

Premium

52w Discount
Market Cap

$285.621m

Small

Price/Earnings

-

Premium

3y Avg

Premium

5y Avg

Financials Overview

Key metrics over the past few years

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin
Revenue

$56.508m

-

1y CAGR

-

3y CAGR

-

5y CAGR
Earnings

-$59.297m

-

1y CAGR

-

3y CAGR

-

5y CAGR
EPS

-$0.59

-

1y CAGR

-

3y CAGR

-

5y CAGR
Book Value

$97.111m

$353.966m

Assets

$256.855m

Liabilities

$113.827m

Debt
Debt to Assets

32.2%

-3.2x

Debt to EBITDA
Free Cash Flow

-$25.981m

-

1y CAGR

-

3y CAGR

-

5y CAGR

Financial Reports

Earnings and other important metrics. Amounts in USD.
No items found.
Press Releases
Statements and updates from the company
ā†‘ TopSummaryPriceFinancialsPress Releases
logo
About usFAQ
All the information presented is collected from official and public documents such as: Quarterly and Annual Reports, 10-K (US), Information Form (Canada), Presentations and the Investor Relations (IR) section of the company's website.
The data displayed by alreits.com is solely for informational purposes, we do not recommend the buying, holding or selling of any of the stocks on the website. If you have no experience in the stock market, please talk to your personal licensed investment advisor before making any decisions.